Literature DB >> 21410356

Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue, and umbilical cord tissue.

Martin A Vidal1, Naomi J Walker, Eleonora Napoli, Dori L Borjesson.   

Abstract

Mesenchymal stem cells (MSCs) from adult and neonatal tissues are intensively investigated for their use in regenerative medicine. The purpose of this study was to compare the onset of replicative senescence in MSCs isolated from equine bone marrow (BMSC), adipose tissue (ASC), and umbilical cord tissue (UCMSC). MSC proliferation (cell doubling), senescence-associated β-galactosidase staining, telomere length, Sox-2, and lineage-specific marker expression were assessed for MSCs harvested from tissues of 4 different donors. The results show that before senescence ensued, all cell types proliferated at ∼1 day/cell doubling. BMSCs significantly increased population doubling rate by passage 10 and ceased proliferation after a little >30 total population doublings, whereas UCMSCs and ASCs achieved about 60 to 80 total population doublings. UCMSC and ASCs showed marked β-galactosidase staining after ∼70 population doublings, whereas BMSCs stained positive by ∼30 population doublings. The onset of senescence was associated with a significant reduction in telomere length averaging 10.2 kbp at passage 3 and 4.5 kbp in senescent cultures. MSCs stained intensively for osteonectin at senescence compared with earlier passages, whereas vimentin and low levels of smooth muscle actin were consistently expressed. Sox-2 gene expression was consistently noted in all 3 MSC types. In conclusion, equine BMSCs appear to senesce much earlier than ASCs and UCMSCs. These results demonstrate the limited passage numbers of subcultured BMSCs available for use in research and tissue engineering and suggest that adipose tissue and umbilical cord tissue may be preferable for tissue banking purposes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21410356     DOI: 10.1089/scd.2010.0589

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  57 in total

1.  Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety.

Authors:  Jorge Paz Rodriguez; Michael P Murphy; Soonjun Hong; Marialaura Madrigal; Keith L March; Boris Minev; Robert J Harman; Chien-Shing Chen; Ruben Berrocal Timmons; Annette M Marleau; Neil H Riordan
Journal:  Int Arch Med       Date:  2012-02-08

2.  Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats.

Authors:  John R Wagner; Takashi Taguchi; Jane Y Cho; Chandrashekhar Charavaryamath; Dominique J Griffon
Journal:  J Vis Exp       Date:  2018-03-30       Impact factor: 1.355

3.  The effect of extended passaging on the phenotype and osteogenic potential of human umbilical cord mesenchymal stem cells.

Authors:  Zhe Shi; Liang Zhao; Gengtao Qiu; Ruixuan He; Michael S Detamore
Journal:  Mol Cell Biochem       Date:  2015-01-03       Impact factor: 3.396

4.  Melatonin reverses H2 O2 -induced premature senescence in mesenchymal stem cells via the SIRT1-dependent pathway.

Authors:  Long Zhou; Xi Chen; Tao Liu; Yihong Gong; Sijin Chen; Guoqing Pan; Wenguo Cui; Zong-Ping Luo; Ming Pei; Huilin Yang; Fan He
Journal:  J Pineal Res       Date:  2015-07-07       Impact factor: 13.007

Review 5.  The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord.

Authors:  Ariff Bongso; Chui-Yee Fong
Journal:  Stem Cell Rev Rep       Date:  2013-04       Impact factor: 5.739

Review 6.  Perinatal stem cells: A promising cell resource for tissue engineering of craniofacial bone.

Authors:  Jia-Wen Si; Xu-Dong Wang; Steve Gf Shen
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

7.  Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI.

Authors:  Aman Khurana; Hossein Nejadnik; Fanny Chapelin; Olga Lenkov; Rakhee Gawande; Sungmin Lee; Sandeep N Gupta; Nooshin Aflakian; Nikita Derugin; Solomon Messing; Guiting Lin; Tom F Lue; Laura Pisani; Heike E Daldrup-Link
Journal:  Nanomedicine (Lond)       Date:  2013-03-27       Impact factor: 5.307

8.  Manufacturing mesenchymal stromal cells for phase I clinical trials.

Authors:  Patrick J Hanley; Zhuyong Mei; Maria da Graca Cabreira-Hansen; Mariola Klis; Wei Li; Yali Zhao; April G Durett; Xingwu Zheng; Yongping Wang; Adrian P Gee; Edwin M Horwitz
Journal:  Cytotherapy       Date:  2013-04       Impact factor: 5.414

9.  Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().

Authors:  Danielle D Carrade; Michael W Lame; Michael S Kent; Kaitlin C Clark; Naomi J Walker; Dori L Borjesson
Journal:  Cell Med       Date:  2012-01-01

10.  Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome.

Authors:  Eduardo B Parisotto; Verónica Vidal; Susana García-Cerro; Sara Lantigua; Danilo Wilhelm Filho; Emilio J Sanchez-Barceló; Carmen Martínez-Cué; Noemí Rueda
Journal:  Neurochem Res       Date:  2016-07-23       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.